Silence Therapeutics plc
NASDAQ:SLNBiotechnology
+$0.19 today
- Market cap
- $936.18M
- Beta
- 1.48
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.80
Volume 1.47M
Average 0.31M
SLN Deferred Revenue (Non-current)
Payments received for goods or services the company will deliver after more than one year.
Silence Therapeutics plcNASDAQ: SLN
Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue (non-current) rises 3.6% from a year ago
Deferred revenue (non-current) stood at $55.22M at the end of Q1 FY2026, up 3.6% from a year earlier and down 0.4% from the prior quarter.
Context
- Deferred revenue (non-current) amounted to 48.0% of total assets at the end of Q1 FY2026, up 19.2 pp from a year earlier.
- Deferred revenue (non-current) increased in 2 of the last 3 fiscal years.
What to watch
Whether deferred revenue (non-current) keeps rising in the next quarterly balance sheet after a +3.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue (Non-current) history
Mixed currencies · from the balance sheet
- Latest · FY2025
- 55.45M USD
- Year-over-year change
- —
| Period | Period end | Deferred Revenue (Non-current) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 55.45M | — |
| FY2024 | 2024-12-31 | 41.38M | -44.8% |
| FY2023 | 2023-12-31 | 75M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Deferred Revenue (Non-current) vs competitors
How SLN compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue (non-current) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +3.6% is the 2nd highest of 5, against a peer median of -49.1%.
- Deferred revenue (non-current) amounts to 48.0% of total assets for SLN, versus a peer median of 2.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $136.35M USD | -58.0% | -44.3% | 4.3% | |
| Mar 2026 | $55.22M USD | +3.6% | — | 48.0% | |
| Sep 2026 | $48.76M USD | -54.8% | -31.6% | 1.7% | |
| Mar 2026 | $36.35M USD | — | — | 12.4% | |
| Sep 2026 | $21.34M USD | — | — | 1.2% | |
| Mar 2026 | €17.33M EUR | -43.3% | — | 17.5% | |
| Mar 2026 | $14.6M USD | +161.4% | -53.9% | 2.5% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding SLN) | — | -49.1% | -44.3% | 2.1% | |
Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · GBP | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Cash & Equivalents | 73.54M | 54.82M | 68.79M | 96.95M | 11.28M |
| Short-term Investments | 0 | 16.33M | 0 | 20.78M | 73.84M |
| Net Receivables | 331K | 915K | 23.98M | 21.5M | 24.61M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.16M | 16.43M | 18.58M | 20.72M | 0 |
| Total Current Assets | 86.33M | 96.69M | 103.15M | 149.72M | 118.66M |
| Property, Plant & Equipment (Net) | 1.94M | 2.2M | 2.31M | 1.58M | 1.75M |
| Goodwill | 7.59M | 8.01M | 9.98M | 7.51M | 10.62M |
| Intangible Assets | 24K | 320K | 362K | 249.32K | 288K |
| Long-term Investments | 301K | 284K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 3.65M | 2.87M | 127K |
| Total Non-current Assets | 9.86M | 10.81M | 16.3M | 12.2M | 12.78M |
| Total Assets | 96.19M | 107.5M | 119.45M | 161.92M | 131.44M |
| Account Payables | 4.07M | 3.19M | 3.35M | 2.95M | 4.41M |
| Short-term Debt | 0 | 0 | 228K | 0 | 0 |
| Tax Payables | 0 | 0 | 475.5K | 715.98K | 0 |
| Deferred Revenue | 0 | 0 | 6.57M | 244.52K | 168K |
| Other Current Liabilities | 4.43M | 9.45M | 8.58M | 2.75M | 5.94M |
| Total Current Liabilities | 15.17M | 21.94M | 22.34M | 13.44M | 13.61M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 75M | 41.38M | 55.45M |
| Other Non-current Liabilities | 72.5M | 63.49M | 0 | 0 | 0 |
| Total Non-current Liabilities | 72.5M | 63.49M | 75.12M | 41.38M | 55.53M |
| Total Liabilities | 87.67M | 85.43M | 97.46M | 54.83M | 69.14M |
| Common Stock | 4.49M | 5.39M | 8.85M | 8.22M | 10.29M |
| Retained Earnings | (222.97M) | (263.26M) | (431.89M) | (378.8M) | (562.57M) |
| Accumulated OCI | 42.67M | 53.27M | 40.36M | (9.41M) | (2.98M) |
| Other Stockholders Equity | 0 | 0 | (51.09M) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 8.53M | 22.07M | 21.99M | 107.1M | 62.3M |
| Total Debt | 137K | 446K | 346K | 93.49K | 160K |
| Net Debt | (73.4M) | (54.37M) | (68.44M) | (96.86M) | (11.12M) |
Silence Therapeutics plc
NASDAQ:SLN
Intrinsic Alpha fair value
Locked
Current Price
$19.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.